A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

437

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

August 29, 2025

Study Completion Date

August 29, 2025

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

OTHER

Ipilimumab placebo

Specified dose on specified days

Trial Locations (78)

1090

Local Institution - 0031, Vienna

1280

Local Institution - 0011, Ciudad Autónoma de Buenos Aires

1419

Local Institution - 0100, Capital Federal

4600

Local Institution - 0032, Wels

5400

Local Institution - 0002, San Juan

5800

Local Institution - 0025, Río Cuarto

7600

Local Institution - 0060, Mar del Plata

8036

Local Institution - 0033, Graz

13273

Local Institution - 0071, Marseille

14004

Local Institution - 0042, Córdoba

14076

Local Institution - 0094, Caen

14080

Local Institution - 0009, Mexico City

Local Institution - 0010, Mexico City

15125

Local Institution - 0023, Athens

15706

Local Institution - 0044, Santiago Compostela

19611

The Reading Hosp Med Ctr Reg Cancer Ctr, West Reading

20007

Local Institution - 0013, Washington D.C.

20141

Local Institution - 0021, Milan

25030

Local Institution - 0075, Besançon

25123

Local Institution - 0082, Brescia

28034

Local Institution - 0036, Madrid

28046

Local Institution - 0035, Madrid

29414

Local Institution - 0084, Charleston

29609

Local Institution - 0074, Brest

30607

Local Institution - 0053, Athens

31000

Local Institution - 0008, Chihuahua City

31008

Local Institution - 0045, Pamplona

33081

Local Institution - 0016, Aviano (PN)

38043

Local Institution - 0080, La Tronche

39008

Local Institution - 0043, Santander

41013

Local Institution - 0041, Seville

41110

Local Institution - 0024, Larissa

43100

Local Institution - 0015, Parma

46009

Local Institution - 0040, Valencia

49055

Local Institution - 0073, Angers

49100

Local Institution - 0069, Angers

52100

Local Institution - 0014, Arezzo

54100

Local Institution - 0078, Nancy

59300

Local Institution - 0091, Valenciennes

64040

Local Institution - 0067, Monterrey

67091

Local Institution - 0093, Strasbourg

75014

Local Institution - 0092, Paris

76000

Local Institution - 0046, Querétaro

83400

Local Institution - 0081, Hyères

92151

Local Institution - 0072, Suresnes

94800

Local Institution - 0068, Villejuif

194044

Local Institution - 0054, Saint Petersburg

200542

Local Institution - 0065, Craiova

400015

Local Institution - 0056, Cluj-Napoca

630099

Local Institution - 0058, Novosibirsk

2520598

Local Institution - 0004, Viña del Mar

8330024

Local Institution - 0003, Santiago

8420383

Local Institution - 0034, Santiago

02114

Local Institution - 0066, Boston

Local Institution - 0088, Boston

02215

Local Institution - 0086, Boston

R8500ACE

Local Institution - 0001, Viedma

X5004FHP

Local Institution - 0005, Córdoba

254 0488

Local Institution - 0012, Viña El Mar

Unknown

Local Institution - 0017, Independencia

602 00

Local Institution - 0020, Brno

656 53

Local Institution - 0097, Brno

100 34

Local Institution - 0019, Prague

140 59

Local Institution - 0018, Prague

06189

Local Institution - 0096, Nice

00128

Local Institution - 0077, Roma

06100

Local Institution - 0006, Mexico City

21-500

Local Institution - 0030, Biała Podlaska

85-796

Local Institution - 0095, Bydgoszcz

41-902

Local Institution - 0062, Bytom

80-219

Local Institution - 0026, Gdansk

61-848

Local Institution - 0029, Poznan

02-781

Local Institution - 0027, Warsaw

1649-035

Local Institution - 0050, Lisbon

020122

Local Institution - 0061, Bucharest

08003

Local Institution - 0038, Barcelona

08035

Local Institution - 0037, Barcelona

08208

Local Institution - 0039, Sabadell

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY